Skip to main content
SpringerLink
Log in

Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

To evaluate the safety and efficacy of neoadjuvant radiohormonal therapy for oligometastatic prostate cancer (OMPC), we conducted a 3 + 3 dose escalation, prospective, phase I/II, single-arm clinical trial (CHiCTR1900025743), in which long-term neoadjuvant androgen deprivation was adopted 1 month before radiotherapy, comprising intensity modulated radiotherapy to the pelvis, and stereotactic body radiation therapy to all extra-pelvic bone metastases for 4–7 weeks, at 39.6, 45, 50.4, and 54 Gy. Robotic-assisted radical prostatectomy was performed after 5–14 weeks. The primary outcome was treatment-related toxicities and adverse events; secondary outcomes were radiological treatment response, positive surgical margin (pSM), postoperative prostate-specific antigen (PSA), pathological down-grading and tumor regression grade, and survival parameters. Twelve patients were recruited from March 2019 to February 2020, aging 66.2 years in average (range, 52–80). Median baseline PSA was 62.0 ng/mL. All underwent RARP successfully without open conversions. Ten patients recorded pathological tumor down-staging (83.3%), and 5 (41.7%) with cN1 recorded negative regional lymph nodes on final pathology. 66.7% (8/12) recorded tumor regression grading (TRG) —I and 25% (3/12) recorded TRG-II. Median follow-up was 16.5 months. Mean radiological progression-free survival (RPFS) was 21.3 months, with 2-year RPFS of 83.3%. In all, neoadjuvant radiohormonal therapy is well tolerated for oligometastatic prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038

    Article  PubMed  Google Scholar 

  2. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2021; 79(2): 263–282

    Article  CAS  PubMed  Google Scholar 

  3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13(1): 8–10

    Article  CAS  PubMed  Google Scholar 

  4. Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V, Wongvipat J, Smith-Jones P, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324(5928): 787–790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study Eur Urol 2014; 65(6): 1058–1066

    PubMed  Google Scholar 

  6. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015; 193(3): 832–838

    Article  PubMed  Google Scholar 

  7. Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, Briganti A. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 2017; 72(2): 289–292

    Article  PubMed  Google Scholar 

  8. Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, Suardi N, Briganti A, Manka L, Nyberg T, Dutton SJ, Wiklund P, Graefen M. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016; 69(5): 788–794

    Article  PubMed  Google Scholar 

  9. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017; 14(1): 15–25

    Article  CAS  PubMed  Google Scholar 

  10. Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, Kerin M. Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol 2019; 25(33): 4850–4869

    Article  PubMed  PubMed Central  Google Scholar 

  11. Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 2017; 19(1): 75

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chan KKW, Saluja R, Delos Santos K, Lien K, Shah K, Cramarossa G, Zhu X, Wong RKS. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis. Int J Cancer 2018; 143(2): 430–437

    Article  CAS  PubMed  Google Scholar 

  13. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7(4): e1000267

    Article  PubMed  PubMed Central  Google Scholar 

  14. Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Bradley M, Sachdeva A, Wyatt B, Basehart V, Zomorodian N, Lin L, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Elashoff D, Schaue D, Reiter RE, Nickols NG. Phase 1 trial of stereotactic body radiation therapy neoadjuvant to radical prostatectomy for patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2020; 108(4): 930–935

    Article  PubMed  PubMed Central  Google Scholar 

  15. Supiot S, Shubbar S, Fleshner N, Warde P, Hersey K, Wallace K, Cole H, Sweet J, Tsihlias J, Jewett MA, Klotz L, Bristow RG. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol 2008; 88(1): 53–60

    Article  PubMed  Google Scholar 

  16. Koontz BF, Quaranta BP, Pura JA, Lee WR, Vujaskovic Z, Gerber L, Haake M, Anscher MS, Robertson CN, Polascik TJ, Moul JW. Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2013; 87(1): 88–93

    Article  PubMed  Google Scholar 

  17. Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A. A phase 1 pilot study of preoperative radiation therapy for prostate cancer: long-term toxicity and oncologic outcomes. Int J Radiat Oncol Biol Phys 2019; 104(1): 61–66

    Article  PubMed  Google Scholar 

  18. Gay HA, Barthold HJ, O’Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W Jr, Gaffney D, Viswanathan AN, Michalski JM. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012; 83(3): e353–e362

    Article  PubMed  PubMed Central  Google Scholar 

  19. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 2010; 37(8): 4078–4101

    Article  PubMed  Google Scholar 

  20. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250(2): 187–196

    Article  PubMed  Google Scholar 

  21. Bandini M, Fossati N, Gandaglia G, Preisser F, Dell’Oglio P, Zaffuto E, Stabile A, Gallina A, Suardi N, Shariat SF, Montorsi F, Karakiewicz PI, Briganti A. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Rev Clin Pharmacol 2018; 11(4): 425–438

    Article  CAS  PubMed  Google Scholar 

  22. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF. Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis. J Clin Oncol 2021; 39(2): 136–144

    Article  CAS  PubMed  Google Scholar 

  23. Kim SH, Park EY, Joo J, Joung JY, Seo HK, Chung J, Lee KH. Effect of neoadjuvant hormone therapy on resection margin and survival prognoses in locally advanced prostate cancer after prostatectomy using propensity-score matching. BioMed Res Int 2018; 2018: 4307207

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lou DY, Fong L. Neoadjuvant therapy for localized prostate cancer: examining mechanism of action and efficacy within the tumor. Urol Oncol 2016; 34(4): 182–192

    Article  CAS  PubMed  Google Scholar 

  25. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000; 42(4): 274–279

    Article  CAS  PubMed  Google Scholar 

  26. Dall’Era MA, Lo MJ, Chen J, Cress R, Hamilton AS. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. Cancer 2018; 124(9): 1921–1928

    Article  PubMed  Google Scholar 

  27. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 2004; 58(1): 3–10

    Article  PubMed  Google Scholar 

  28. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med 2020; 61(8): 1153–1160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl 2021; 23(4): 429–436

    Article  PubMed  PubMed Central  Google Scholar 

  30. McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis 2018; 21(3): 364–372

    Article  PubMed  Google Scholar 

  31. McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ, Chang PK, Wagner A, Zhang Z, Kibel AS, Taplin ME. Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol 2021; 205(6): 1689–1697

    Article  PubMed  Google Scholar 

  32. Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F, Joniau S. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol 2021; 18(12): 739–762

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study is supported by the 2021 Changhai Hospital Educational Sponsorship Fund (No. CHPY2021B24, General Program, YC), the 2021 Naval Medical University Basic Science Research Youth Start-up Fund (No. 2021QN29, YC), the First Affiliated Hospital of Navy Medical University “234 Subject Climbing Program” (No. 2019YPT004, HZ), the First Affiliated Hospital of Naval Medical University “Youth Development Program” (No. 2021JCQNO3, XZ) and the First Affiliated Hospital of Naval Medical University “Youth Startup Fund” (Nos. 2021QN29 and 2020QNB10, XZ).

Author information

Author notes

  1. Yifan Chang and Xianzhi Zhao contributed equally to this paper.

Authors and Affiliations

  1. Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China

    Yifan Chang, Yutian Xiao, Shi Yan & Ye Wang

  2. Department of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China

    Xianzhi Zhao & Huojun Zhang

  3. Department of Urology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China

    Weidong Xu & Shancheng Ren

Authors
  1. Yifan Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xianzhi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yutian Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shi Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weidong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ye Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huojun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shancheng Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Huojun Zhang or Shancheng Ren.

Ethics declarations

Yifan Chang, Xianzhi Zhao, Yutian Xiao, Shi Yan, Weidong Xu, Ye Wang, Huojun Zhang, and Shancheng Ren declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975. Informed consent was obtained from all patients for being included in the study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, Y., Zhao, X., Xiao, Y. et al. Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial. Front. Med. 17, 231–239 (2023). https://doi.org/10.1007/s11684-022-0939-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-022-0939-9

Keywords

Search

Navigation